These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33964455)

  • 21. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
    Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
    Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
    Chow SC; Lam PY; Lam WC; Fung NSK
    Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timing of laser following intravitreal anti-vascular endothelial growth factor injections for aggressive posterior zone 1 retinopathy of prematurity.
    Vinekar A
    Indian J Ophthalmol; 2021 Aug; 69(8):1988-1989. PubMed ID: 34304161
    [No Abstract]   [Full Text] [Related]  

  • 27. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential Short Interval Anti-VEGF for the Treatment of Stage 4 Retinopathy of Prematurity.
    Hamichi SE; Saigal K; Anzaldo EF; Gold A; Berrocal AM; Murray TG
    Ophthalmic Surg Lasers Imaging Retina; 2022 Mar; 53(3):159-163. PubMed ID: 35272561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing reactivation and retreatment for three doses of bevacizumab in type 1 retinopathy of prematurity.
    Chopra J; Haider KM; Boente CS
    J AAPOS; 2024 Apr; 28(2):103866. PubMed ID: 38458598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab.
    Wang W; Hong GJ; Stinnett SS; Freedman SF; Wallace DK; Prakalapakorn SG
    J AAPOS; 2022 Dec; 26(6):323-326. PubMed ID: 36152755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.
    Sato T; Wada K; Arahori H; Kuno N; Imoto K; Iwahashi-Shima C; Kusaka S
    Am J Ophthalmol; 2012 Feb; 153(2):327-333.e1. PubMed ID: 21930258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
    Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO
    Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
    Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
    Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series.
    Martínez-Castellanos MA; González-H León A; Romo-Aguas JC; Gonzalez-Gonzalez LA
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):767-772. PubMed ID: 31953595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity.
    Khodabande A; Niyousha MR; Roohipoor R
    J AAPOS; 2016 Dec; 20(6):490-492. PubMed ID: 27794470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
    JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract]   [Full Text] [Related]  

  • 39. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab.
    Ittiara S; Blair MP; Shapiro MJ; Lichtenstein SJ
    J AAPOS; 2013 Jun; 17(3):323-5. PubMed ID: 23607977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity.
    Murakami T; Sugiura Y; Okamoto F; Okamoto Y; Kato A; Hoshi S; Nagafuji M; Miyazono Y; Oshika T
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2849-2855. PubMed ID: 33744981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.